Join
CTI BioPharma Corp. (DE) logo

CTIC

NASDAQ

CTI BioPharma Corp. (DE)

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO1997
$9.09-0.01 (-0.05%)
FollowWebsite
News25/Ratings7

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Latest news

25 items

CTIC FAQ

7 questions
  • What does CTI BioPharma Corp. (DE) do?
    CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed...
  • Where does CTIC stock trade?
    CTI BioPharma Corp. (DE) (CTIC) is listed on NASDAQ.
  • What sector and industry is CTIC in?
    CTI BioPharma Corp. (DE) operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did CTI BioPharma Corp. (DE) go public?
    CTI BioPharma Corp. (DE) (CTIC) completed its IPO in 1997.
  • What are analysts saying about CTIC?
    CTI BioPharma Corp. (DE) has had 7 recent analyst actions on file. The most recent action was from SVB Leerink: Outperform with a $1300.00 price target on 2022-10-17. Recent price targets range from $500.00 to $1300.00.
  • What companies are similar to CTIC?
    Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CTIC side-by-side with any of them on Quantisnow.
  • How can I track CTIC on Quantisnow?
    Quantisnow aggregates CTI BioPharma Corp. (DE)'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CTIC to receive live email and push alerts on every new disclosure.